Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128846 | 0.79 | CA1 (0.42) | ALDH1A1HTTL3MBTL1MAPK1 | |
| SCHEMBL9464711 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL27632106 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL1679636 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL5323046 | 0.77 | LMNA (0.68) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL2991209 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL11793161 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL1662507 | 0.75 | L3MBTL1 (0.41) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL44853 | 0.74 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL171307 | 0.74 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1786766-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-7741351-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1786766-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006015829-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GRIN1, GRM1, GLRA1 | ALDH1A1 1051/4885LMNA 3935/4885MEN1 2262/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885LMNA 2719/4885MEN1 675/4885 |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | ALDH1A1 2912/4885LMNA 3667/4885MEN1 4300/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | ALDH1A1 3327/4885LMNA 1180/4885MEN1 2/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | ALDH1A1 3327/4885LMNA 1180/4885MEN1 2/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | ALDH1A1 985/4885LMNA 835/4885MEN1 263/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885LMNA 2719/4885MEN1 675/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | ALDH1A1 3230/4885LMNA 1233/4885MEN1 15/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | ALDH1A1 3327/4885LMNA 1180/4885MEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.